Antiarrhythmic activity of taurhythman.
Antiarrhythmic properties of taurhythman were demonstrated on experimental models of ventricular (early occlusion and calcium chloride-induced) and atrioventricular (aconitine-induced) arrhythmias. The preparation reduced or prevented episodes of paroxysmal tachycardia and ventricular fibrillation, decreased the incidence of arrhythmias, and increased the lethal dose (LD) of arrhythmogenic agents. By its efficiency, taurhythman was superior to procainamide and comparable to lidocaine.
Sapronov
N S
NS
S. V. Anichkov Department of Neuropharmacology, State Research Institute of Experimental Medicine, Russian Academy of Medical Sciences, St. Petersburg. sns@iem.spb.ru
Gavrovskaya
L K
LK
Krylova
I B
IB
Evdokimova
N R
NR
D000157:Aconitine / Q000494:pharmacology; D017738:Alkanesulfonic Acids / Q000494:pharmacology*; D000818:Animals; D000889:Anti-Arrhythmia Agents / Q000494:pharmacology; D001145:Arrhythmias, Cardiac / Q000188:drug therapy*; D002316:Cardiotonic Agents / Q000494:pharmacology*; D004195:Disease Models, Animal; D006323:Heart Arrest; D008012:Lidocaine / Q000494:pharmacology*; D008297:Male; D011342:Procainamide / Q000494:pharmacology*; D051381:Rats; D013614:Tachycardia, Paroxysmal / Q000188:drug therapy / Q000517:prevention & control*; D014693:Ventricular Fibrillation / Q000188:drug therapy / Q000517:prevention & control*
D017738:Alkanesulfonic Acids; D000889:Anti-Arrhythmia Agents; D002316:Cardiotonic Agents; C513229:N-(1-methyl-2-phenylethyl)aminoethane sulfonic acid isopropylamide; D008012:Lidocaine; D011342:Procainamide; D000157:Aconitine